Form 4: Repare Therapeutics Inc. Executive Acquires Shares and Options

Michael Zinda, EVP and Chief Scientific Officer of Repare Therapeutics Inc., reports acquisition of shares and stock options.

Summary

• On March 4, 2025, Michael Zinda, the EVP and Chief Scientific Officer of Repare Therapeutics Inc., reported changes in beneficial ownership to the SEC.
• Zinda acquired 14,000 common shares in the form of restricted stock units (RSUs).
• These RSUs vest in three equal installments on March 4, 2026, March 4, 2027, and March 4, 2028, contingent upon continued service.
• Zinda also acquired two employee stock option grants, one for 75,000 shares and another for 85,000 shares, both with an exercise price of $1.17.
• The first option for 75,000 shares vests fully on March 4, 2026, subject to continued service.
• The second option for 85,000 shares vests 25% on March 4, 2026, with the remaining shares vesting monthly over the subsequent 36 months, also subject to continued service.
• Following these transactions, Zinda directly owns 85,908 common shares.
• Zinda also owns 75,000 and 85,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of executive compensation. The acquisition of shares and options could be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of shares and options by a key executive could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon the Reporting Person's continued service with the company.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biopharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biopharmaceutical industry to incentivize and retain key personnel.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar compensation structures for their executives.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they reflect executive confidence.
• Employees may view the executive's stock ownership as a positive sign for the company's future.

Key Dates